On December 14, 2022, Hexima Limited announced that it has received a requisition notice from Merchant Biotech Fund requesting the general meeting of the Company will be held on January 31, 2023, that to remove Michael Aldridge, Jake Nunn and Scott Robertson as a director of the Company and to appoint Chris Mews as a director of the Company.